| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 28.76 | 13062 |
| Intrinsic value (DCF) | 0.62 | 184 |
| Graham-Dodd Method | 0.04 | -84 |
| Graham Formula | 0.16 | -28 |
Klea Holding SA (formerly Visiomed Group SA) is a Paris-based healthcare technology company specializing in innovative telemedicine and remote monitoring solutions. Operating in France and internationally, Klea offers the BewellConnect ecosystem, which provides comprehensive digital health services including teleconsultation, remote patient monitoring, hospital surveillance, and tele-expertise. The company also markets Smart Salem, a medical fitness screening device. Founded in 2007 and listed on Euronext Paris, Klea targets the growing telemedicine market, which is being driven by increasing demand for remote healthcare solutions and digital transformation in the medical sector. With a market capitalization of approximately €53.7 million, Klea positions itself at the intersection of healthcare and technology, leveraging digital tools to improve patient care accessibility and efficiency.
Klea Holding presents a speculative investment opportunity in the rapidly evolving telemedicine sector. The company's focus on digital health solutions aligns with global healthcare trends toward remote care, but its small market cap (€53.7M) and negative beta (-1.178) suggest high volatility and potential idiosyncratic risks. While revenue stands at €17.26M with net income of €1.4M, indicating some operational traction, the lack of EPS and dividends may deter income-focused investors. The balance sheet shows moderate liquidity (€3.3M cash) against €5.88M debt. Investors should weigh Klea's niche positioning in telemedicine against its limited scale and the competitive intensity of the healthcare technology sector.
Klea Holding operates in the competitive telemedicine and digital health monitoring space, where its primary advantage lies in its integrated BewellConnect platform offering multiple telehealth services. The company's focus on the French market provides regional expertise but limits its scale compared to global players. Klea's Smart Salem device differentiates it from pure software telehealth providers, though adoption depends on healthcare provider partnerships. The company's 2024 rebranding from Visiomed to Klea suggests strategic repositioning, but its small size makes it vulnerable to competition from better-capitalized firms. Klea's negative beta indicates performance uncorrelated with broader markets, potentially appealing to diversification-seeking investors but also reflecting its niche, high-risk profile. The €766K in capital expenditures signals ongoing investment in technology, critical for maintaining competitiveness in this innovation-driven sector.